COMMUNIQUÉS West-GlobeNewswire

La FDA accorde le statut de médicament orphelin et médicament pour une maladie pédiatrique rare (Rare Pediatric Disease Designation-RPDD) au produit candidat de Cellectis UCART22 pour le traitement de la leucémie lymphoblastique aiguë (LLA)
25/07/2024
o La LLA, qui représente 10% des cas de leucémie dans les États Unis, progresse rapidement, pouvant être fatale en quelques semaines ou quelques mois si elle n'est pas traitée 1 . o Il existe un besoin urgent de [...]
Travere Therapeutics to Report Second Quarter 2024 Financial Results
25/07/2024
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter 2024 financial results on Thursday, August 1, 2024, after the close of the U.S. [...]
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
25/07/2024
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients [...]
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
25/07/2024
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Cronos Group Inc. to Hold 2024 Second Quarter Earnings Conference Call on August 8, 2024
25/07/2024
TORONTO, July 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2024 second quarter earnings conference call on Thursday, August 8, 2024 at 8:30 a.m. ET [...]
The Ensign Group Reports Second Quarter 2024 Results; Raises Annual Earnings and Revenue Guidance
25/07/2024
Conference Call and Webcast scheduled for tomorrow, July 26, 2024 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM [...]
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
25/07/2024
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, announced [...]
Sensus Healthcare to Host Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 8, 2024
25/07/2024
BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological [...]
TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference
25/07/2024
MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the [...]
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
25/07/2024
BASEL, Switzerland and LONDON and NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 8, 2024, to [...]
iSpecimen to Report Second Quarter 2024 Results on August 6, 2024
25/07/2024
LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
25/07/2024
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature - Company anticipates annualized [...]
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
25/07/2024
- Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody ® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck’s anti-PD-1 therapy KEYTRUDA* ( [...]
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
25/07/2024
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and [...]
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
25/07/2024
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis. 1 This patent strengthens Inventiva’s intellectual property with respect to lanifibranor [...]
Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor
25/07/2024
► L'Office des brevets japonais a accordé la demande de brevet d'Inventiva concernant l'utilisation de lanifibranor pour le traitement de la cirrhose 1 . ► Ce brevet renforce la propriété intellectuelle d’Inventiva [...]
Cytokinetics to Announce Second Quarter Results on August 8, 2024
25/07/2024
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at 4:00 PM Eastern Time. [...]
Canadian Red Cross launches appeal for people affected by Alberta Wildfires
25/07/2024
OTTAWA, July 25, 2024 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the 2024 Alberta Wildfires Appeal to help people and communities impacted by wildfires in Alberta. Donations to the Canadian Red Cross will [...]
La Croix-Rouge canadienne lance un fonds de secours pour les personnes touchées par les feux de forêt en Alberta
25/07/2024
OTTAWA, 25 juill. 2024 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne a mis sur pied le Fonds de secours : Feux de forêt de 2024 en Alberta afin d’aider les personnes et les communautés touchées par les incendies dans la [...]

Pages